Thioredoxins, mitochondria, and hypertension

18Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Endothelial dysfunction, often demonstrated by the loss of the endothelial cell's ability to cause vasodilation in response to appropriate stimuli, is one of the earliest events in the development of atherosclerosis. This has led to intense investigation of the factors affecting both the production and the degradation of NO, the endothelium-derived relaxing factor and a primary mediator of endothelial function. Reactive oxygen species (ROS), particularly superoxide anion, are well known to inhibit NO, and therefore the mechanisms by which endothelium regulates production of ROS are also of high interest. In this issue of The American Journal of Pathology, Zhang et al1 demonstrate regulation of such events by a mitochondria-specific thioredoxin, which reduces oxidative stress and increases NO bioavailability, thus preserving vascular endothelial cell function and preventing atherosclerosis development. Copyright © American Society for Investigative Pathology.

Cite

CITATION STYLE

APA

Patwari, P., & Lee, R. T. (2007). Thioredoxins, mitochondria, and hypertension. American Journal of Pathology. American Society for Investigative Pathology Inc. https://doi.org/10.2353/ajpath.2007.061243

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free